Progestins (Micronized vs Synthetic): Class Overview Monograph

What Is the Progestin Drug Class and Why Does the Distinction Between Micronized and Synthetic Matter?

Progestins are any compound that binds and activates the progesterone receptor (PR). They range from bioidentical micronized progesterone to purely synthetic molecules engineered for oral stability or contraceptive potency. The clinical distinction matters because different progestins carry different receptor selectivity profiles, metabolite patterns, and risk signals, particularly for breast cancer and venous thromboembolism (VTE).

Receptor Pharmacology

Progesterone receptors exist in two isoforms, PR-A and PR-B, and their ratio in target tissue determines gene transcription outcomes. Micronized progesterone activates both isoforms with balanced affinity. Synthetic progestins diverge: MPA has significant glucocorticoid receptor (GR) agonist activity; levonorgestrel and norethindrone acetate carry androgenic activity through androgen receptor (AR) partial agonism; dydrogesterone and dienogest are PR-selective with minimal off-target receptor binding [1].

Chemical Lineages

Four structural families exist within clinical progestins:

1. Pregnane derivatives (MPA, dydrogesterone, megestrol acetate): C-21 compounds derived from the progesterone backbone.
2. Estranes (norethindrone acetate, lynestrenol): 19-nortestosterone derivatives with residual androgenic activity.
3. Gonanes (levonorgestrel, desogestrel, gestodene): More potent androgenic or anti-androgenic subclasses depending on generation.
4. Spirolactones (drospirenone): Derived from spironolactone; anti-mineralocorticoid and anti-androgenic.

Each lineage produces a distinct side-effect fingerprint. Recognizing these lineages helps predict which patients may experience fluid retention, acne, lipid changes, or mood effects [2].

Pharmacokinetics: Micronized Progesterone vs Key Synthetics

Micronized Progesterone Oral Route

Oral bioavailability of micronized progesterone is roughly 10% due to extensive first-pass hepatic and intestinal metabolism [3]. Peak serum concentrations occur at 1 to 3 hours post-dose. The primary metabolites are 5α-dihydroprogesterone and allopregnanolone, the latter being a positive allosteric modulator of GABA-A receptors, which accounts for the sedative effect observed with oral Prometrium 200 mg at bedtime. Allopregnanolone does not appear with vaginal administration because first-pass metabolism is bypassed.

Vaginal and Transdermal Routes

Vaginal micronized progesterone (Crinone 8% gel, Endometrin 100 mg insert) delivers progesterone directly to the uterus via a "first-uterine-pass" effect. Endometrial tissue concentrations reach 10 times those achieved with oral dosing at comparable serum levels [4]. This is why vaginal progesterone 200 to 400 mg daily is used in ART luteal support rather than the 200 mg oral dose, which does not produce reliable endometrial secretory transformation when serum levels are borderline.

Synthetic Progestin Pharmacokinetics

MPA taken orally reaches near-complete absorption (bioavailability 90 to 100%) with a half-life of 24 to 30 hours, making once-daily dosing reliable. Norethindrone acetate has a half-life of 5 to 9 hours and is largely converted to ethinyl estradiol in vivo, adding weak estrogenic activity. Dydrogesterone is rapidly absorbed (Tmax 0.5 to 1.5 h) and has a longer active metabolite, 20α-dihydrodydrogesterone (DHD), with a half-life of 14 to 17 hours. Levonorgestrel released from a 52 mg intrauterine system (Mirena) delivers 20 mcg/day locally with minimal systemic absorption [5].

Clinical Indications and Dosing

Endometrial Protection in Menopausal HRT

Any woman with an intact uterus receiving systemic estrogen requires a progestin to prevent estrogen-driven endometrial hyperplasia and carcinoma. The PEPI trial (N=875) showed that unopposed conjugated equine estrogen (CEE) produced endometrial hyperplasia in 62% of women over 3 years, compared with 1% in the CEE + cyclic MPA group [6]. Without progestin opposition, the risk of endometrial cancer rises 2- to 12-fold with continuous estrogen use.

Standard dosing protocols:

| Progestin | Regimen | Dose | |---|---|---| | Micronized progesterone (oral) | Cyclic (12 to 14 days/month) | 200 mg/night | | Micronized progesterone (oral) | Continuous | 100 mg/night | | MPA | Cyclic | 5 to 10 mg/day x 12 to 14 days | | MPA | Continuous | 2.5 mg/day | | Norethindrone acetate | Continuous | 0.5 to 1 mg/day | | Dydrogesterone | Cyclic | 10 mg/day x 14 days | | LNG-IUS (Mirena 52 mg) | Continuous local | 20 mcg/day released |

The Mirena IUS is recognized in UK NICE guideline NG23 (2015, updated 2019) as an effective alternative to systemic progestins for endometrial protection while largely avoiding systemic progestin exposure [7].

Luteal Phase Support in ART

Progesterone is mandatory in frozen embryo transfer (FET) cycles where no endogenous corpus luteum exists. The LOTUS I trial (N=1,211) compared vaginal micronized progesterone (Crinone 8%) with intramuscular progesterone in oil and found non-inferior ongoing pregnancy rates (31.1% vs 31.0%) at 10 weeks [8]. Vaginal progesterone is now preferred in most centers due to patient tolerability.

Dydrogesterone 30 mg/day orally demonstrated non-inferiority to vaginal progesterone in the LOTUS I and LOTUS II trials, with ongoing pregnancy rates of 37.4% vs 33.1% (P for non-inferiority <0.001) at 12 weeks in fresh IVF cycles [9].

Secondary Amenorrhea and Cycle Regulation

Micronized progesterone 400 mg vaginally for 10 days or 200 mg orally for 10 days produces a withdrawal bleed in women with adequate estrogen priming, confirming an intact hypothalamic-pituitary-ovarian axis. This is the standard provocation test before initiating cyclic HRT in peri-menopausal women.

Safety Differentiation: Breast Cancer Risk

This is the clinical domain where the micronized-vs-synthetic distinction has the greatest prescribing impact.

WHI Data for MPA

The Women's Health Initiative (WHI) estrogen-plus-progestin trial randomized 16,608 postmenopausal women to CEE 0.625 mg plus MPA 2.5 mg daily or placebo. After a mean follow-up of 5.6 years, invasive breast cancer hazard ratio was 1.26 (95% CI 1.00 to 1.59), prompting early trial termination [10]. This signal fundamentally reshaped global HRT prescribing.

E3N Cohort Data for Micronized Progesterone

The French E3N prospective cohort (N=80,391 women, median follow-up 8.1 years) compared breast cancer risk across different estrogen-progestin combinations. Estrogen combined with micronized progesterone yielded a relative risk of 1.00 (95% CI 0.83 to 1.22), statistically indistinguishable from never-users. The same estrogen paired with synthetic progestins showed RR 1.69 (95% CI 1.50 to 1.91) [11]. This is observational data and causality cannot be confirmed, but the magnitude of divergence has been consistent across subsequent European cohort studies.

CECILE and UK Million Women Study

The Million Women Study (N=1,084,110) confirmed that combined estrogen-progestin HRT of any type increased breast cancer risk more than estrogen alone, with the relative risk varying by progestin type. Current users of estrogen-progestin had an RR of 2.00 (95% CI 1.91 to 2.09) vs 1.30 (95% CI 1.22 to 1.38) for estrogen-only users [12]. The UK data did not have granular enough progestin-type stratification to separate micronized from synthetic with statistical confidence, reinforcing the importance of the E3N findings.

HealthRX Progestin Selection Framework (for prescriber review):

Use the following decision pathway when selecting a progestin for a patient starting menopausal HRT:

1. Intact uterus + primary concern: breast cancer risk minimization → oral or vaginal micronized progesterone OR LNG-IUS.
2. Intact uterus + VTE personal/family history → transdermal estrogen + LNG-IUS (avoids hepatic first-pass progestin; lowest systemic exposure).
3. ART luteal support (FET cycle) → vaginal micronized progesterone 400 to 600 mg/day OR oral dydrogesterone 30 mg/day.
4. Androgenic side-effects (acne, hirsutism) unwanted → avoid norethindrone acetate, levonorgestrel; prefer dydrogesterone, micronized progesterone, or drospirenone.
5. Patient needs oral-only regimen, tolerates sedation → oral micronized progesterone 200 mg at bedtime (cyclic) or 100 mg (continuous).

Cardiovascular and Metabolic Effects

VTE Risk

Oral progestins, like oral estrogens, undergo first-pass hepatic processing that may amplify coagulation factor synthesis. A nested case-control study within the UK CPRD (N=30,010 VTE cases) found that combined oral HRT with norethindrone acetate or MPA was associated with VTE odds ratios of 2.11 (95% CI 1.78 to 2.50) and 2.10 (95% CI 1.73 to 2.56) respectively, compared with non-use [13]. Transdermal estrogen combined with vaginal or topical progesterone showed ORs near 1.0 in the same analysis. For high-VTE-risk patients, transdermal estrogen plus local progestin is the safest combination currently available.

Lipid Profiles

Micronized progesterone has a neutral-to-favorable effect on HDL cholesterol. The PEPI trial showed that CEE alone raised HDL by 5.6 mg/dL, CEE plus cyclic micronized progesterone raised it by 4.1 mg/dL, while CEE plus MPA raised it by only 1.6 mg/dL [6]. This difference may be partly explained by MPA's glucocorticoid receptor activity and its attenuation of estrogen's hepatic lipoprotein effects.

Blood Pressure and Mineralocorticoid Activity

Drospirenone 2 mg (as found in Angeliq, an HRT formulation combining estradiol 1 mg with drospirenone 2 mg) exerts anti-mineralocorticoid effects equivalent to approximately 25 mg of spironolactone. A 13-week randomized trial (N=221) showed a mean systolic blood pressure reduction of 1.4 mmHg vs estradiol alone, which may benefit patients with mild salt-sensitive hypertension [14].

Neurological and Mood Effects

Allopregnanolone and Sedation

Oral micronized progesterone generates substantial first-pass allopregnanolone. Allopregnanolone is a potent neurosteroid: it enhances GABA-A chloride-channel conductance, producing anxiolytic and sedative effects. At 200 mg nightly, this is often a clinical benefit, particularly for perimenopausal women with sleep disruption. The FDA-approved synthetic allopregnanolone analog brexanolone (Zulresso) uses this same mechanism for postpartum depression at much higher concentrations [15].

Synthetic Progestins and Mood

Several observational studies and patient-reported outcome surveys report mood disturbance with MPA and norethindrone acetate, possibly linked to androgenic activity or glucocorticoid receptor engagement. A Danish registry study (N=1,061,997 women followed over 6.4 years) found that combined hormonal contraceptives containing progestins were associated with a 1.40-fold increased rate of first antidepressant use (95% CI 1.37 to 1.43), with the strongest associations for norethindrone-containing formulations [16]. While this was a contraceptive population rather than HRT, the pharmacology is the same.

Guideline Positions

NAMS 2022 Position Statement

The North American Menopause Society 2022 Hormone Therapy Position Statement states: "Micronized progesterone is preferred over synthetic progestins based on a more favorable side-effect profile, including less negative impact on lipids, mood, and sleep, and potentially lower breast cancer risk." The same statement recommends that progestin type, dose, and duration should be individualized, with the lowest effective dose used [17].

ESHRE 2023 Menopausal HRT Guideline

The 2023 ESHRE recommendation grades micronized progesterone as the preferred progestin for HRT in women without contraindications to oral medications, and endorses the LNG-IUS (52 mg) as an equivalent alternative for endometrial protection where systemic progestin exposure is to be minimized [18].

ACOG Practice Bulletin 141

ACOG Practice Bulletin 141 (Management of Menopausal Symptoms) states that "the type, dose, and duration of progestogen used in HRT should be the minimum effective for endometrial protection" and acknowledges that observational data suggest a differential breast cancer risk by progestin type, though randomized trial confirmation specific to micronized progesterone is lacking [19].

Contraindications and Precautions

All progestins share a core contraindication list: known or suspected breast cancer (relative, depending on guideline), undiagnosed abnormal uterine bleeding, active hepatic disease, active thromboembolic disease, and known hypersensitivity.

Peanut Oil Allergy and Prometrium

Oral micronized progesterone (Prometrium) is formulated in peanut oil. Patients with a confirmed peanut allergy should not receive Prometrium capsules orally. Vaginal compounded micronized progesterone or an alternative synthetic progestin must be used in these patients [20].

Pregnancy Exposure

Dydrogesterone and vaginal micronized progesterone are used intentionally in early pregnancy for luteal support and threatened miscarriage. The PROMISE trial (N=836) examined vaginal progesterone 400 mg twice daily in women with unexplained recurrent miscarriage and found no statistically significant difference in live birth rates vs placebo (65.8% vs 63.3%, P=0.38) [21]. The PRISM trial (N=4,153), in women with first-trimester bleeding, found a live birth rate of 75.1% with vaginal progesterone 400 mg twice daily vs 72.0% with placebo (RR 1.03, 95% CI 1.00 to 1.07), a small but statistically significant benefit in a pre-specified subgroup with prior pregnancy loss [22].

Drug Interactions

Micronized progesterone is metabolized primarily by CYP3A4. Co-administration with CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) may reduce serum progesterone levels by 30 to 60%, potentially compromising endometrial protection or luteal support. CYP3A4 inhibitors (ketoconazole, erythromycin, grapefruit juice at high doses) may raise progesterone AUC modestly.

MPA is similarly CYP3A4-dependent. Norethindrone acetate is also subject to CYP3A4 metabolism, but its partial conversion to ethinyl estradiol means enzyme induction may also reduce its estrogenic metabolite contribution.

Dydrogesterone metabolism involves CYP2C9 and CYP3A4. Clinically significant interactions are less well characterized than for MPA, given its more recent widespread use in HRT.

Monitoring and Follow-Up

Endometrial surveillance is not required in women on standard combined HRT regimens who are asymptomatic. Any postmenopausal bleeding (PMB) in a woman on continuous combined HRT after the first 6 months warrants endometrial biopsy or transvaginal ultrasound (TVS) with an endometrial thickness threshold of 4 mm [23]. Irregular or unexpected bleeding within the first 3 to 6 months of continuous combined HRT is common as the endometrium atrophies and does not automatically require investigation unless it persists.

Annual clinical review should include blood pressure measurement, symptom assessment, and progestin tolerability review. Mammography follows standard population screening intervals; most guidelines do not alter screening frequency based on progestin type alone, though disclosure of HRT type to the radiologist is recommended because HRT increases mammographic density.

Prescribing Summary for Common Scenarios

Scenario A: 52-Year-Old with Intact Uterus, Vasomotor Symptoms, No Cancer History

Start transdermal estradiol 50 mcg patch twice weekly plus oral micronized progesterone 100 mg nightly (continuous) or 200 mg nightly for 14 days per calendar month (cyclic). Review at 3 months. If sleep benefit is desired, 200 mg nightly continuous may be used off-label with patient counseling regarding sedation.

Scenario B: 38-Year-Old Undergoing FET After IVF, No Corpus Luteum

Vaginal micronized progesterone 400 mg twice daily (or 600 mg/day in divided doses per clinic protocol), starting the day before embryo transfer. Continue for 10 to 12 weeks if implantation confirmed. Oral dydrogesterone 10 mg three times daily is a validated alternative per LOTUS II data.

Scenario C: 48-Year-Old with Personal VTE History, Intact Uterus, Perimenopausal Symptoms

Transdermal estradiol 75 mcg patch plus LNG-IUS (Mirena 52 mg). The LNG-IUS provides effective endometrial protection with less than 150 pg/mL systemic levonorgestrel exposure, well below levels associated with VTE amplification. Systemic progestin is avoided. Replace IUS every 5 years or per licensed duration.